References
- Med.J.Aust.Dec. v.159 no.11-12 The Diabetes Control and Complications Trial(DCCT).A milestone in diabetes management Chrisholm,D.J.
- Grop.Lancet. v.12 no.352(9131) Intensive bleed-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes(UKPDS33).UK Prospective Diabetes Stedy(UKPDS)
- Diabetes Res.Clin.Pract. v.28 no.103 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes melitus Ohkuba,Y.;Kishikawa,H.;Araki,E.
- Am.J.Med. v.96 no.25S Diabetic dyslipidemia Betteridge,D.J.
- Diabetes Metab.Rev. v.10 no.225 Insulin and lipoprotein metabolism with special reference to the diabetic state Tomkin,G.H.;Owens,D.
- Endocrine Rev. v.15 no.263 Dyslipidemia in non-insulin-dependent diabetes melitus Howard,B.V.;Howard,W.J.
- Diabetes Rev. v.3 no.408 Epidemiology of diabetic dyslipidemia Laakso,M.
- Diabetes v.31 no.126 Abnormal concentration of high density lipoprotein in non-insulin-dependent diabetics Biesbroeck,R.C.;Albers,J.J.;Wahl,P.W.;Weinberg,C.R.;Basett,M.L.;Bierman,E.L.
- Am.J.Epiemiol. v.115 no.657 Plasma lipids and diabetes mellitus in an adult community Barret-Connor,E.;Grundy,S.M.;Holbrook,M.J.
- Diabetes Care. v.16 no.434 Risk factors and 12-yrcardiovascular mortality for men screened in the multiple risk factor intervention trial Unsitupa,M.;Siitonen,O.;Voutilainen,E.;Aro,A.;Hersioo,K.;Pyorala,K.
- Diabetes v.34 no.8 Meta-bolism of LDL from patients with diabetic hypergly-ceridemia by cultured human skin fibroblasts Hiramatzu,K.;Bierman,E.L.;Chait,A.
- Arch.Intern.Med. v.130 no.833 Atherosclerosis in diabetes mellitus.Correlations with serum lipid levels,adiposity and serum insulin level. Santon,R.J.;Willis,P.W.;Fanjas,S.S.
- Diabetologia v.32 no.300 Hypertrigly-ceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes:results from the 11-year fallow-up of the Paris Prospective Study. Fontbonne,A.;Eschwege,E.;Cambien,F.;Richard,J.L.;Ducimetiere,P.;Thibult,N.
- Br.Med.J. v.1 no.883 High density and low density lipoproteins and prevalence of vascular.Disease in diabetes mellitus Reckless,J.P.D.;Betteridge,D.J.;Wu,P.;Payne,B.;Galton,D.J.
- Diabetologia v.27 no.568 Clinical macrovascular disease in diabetic subjects:logistic regression analysis of risk variables Welborn,T.A.;Knuiman,M.;McCann,V.;Stanton,K.;Constable,I.J.
- Curr.Opin.Lipidol. v.6 no.360 Selection of appropriate type and intensity of lipid-lowering therapy Tikkanen,M.J.
- Diabetes Care. v.21 no.S36 Management of dyslipidemia in adults with diabetes American Diabetes Association
- Am.J.Cardiol. v.66 no.16B Comparison of the effects of lovastatin and Gemfibrozil on lipids and glucose control in non-insulin dependent diabetes mellitus Goldberg,R.;La Belle,P.;Zupkis,R.;Ronca,P.
- J.Clin.Endocrinol.Metab. v.73 no.503 Effect of gemfibrozil treatment in sulfonylurea-treated patients with non-insulin-dependent diabetes mellitus Shen,D.C.;Fuh,M.M.T.;Shieh,S.M.;Chen,Y.D.;Reaven,G.M.
- J.Clin.Endocrinol.Metab. v.73 no.503 Effect of gemfibrozil treatment in sulfonylurea-treated patients with non-insulin-dependent diabetes mellitus Shen,D.C.;Fuh,M.M.T.;Shieh,S.M.;Chen,Y.D.;Reaven,G.M.
- Atherosclerosis v.101 no.79 Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus.Relations to lipolytic enzymes and to the cholesterol ester transfer protein activity Kahri,J.;Vuorine-Markkola,H.;Tilly-Kiesi,M.;Lahdenpera,S.;Taskinen,M.R.
- Diabetes Care. v.16 no.584 Effects of gemfibrozil on low-density lipoprotein particle size,density distribution and composition in patients with type Ⅱdiabetes Lahdenpera,S.;Tilly-Kiesi,M.;Vuorinen-Markkola,M.;Kuusi,T.;Tskinen,M.R.
- JAMA. v.231 no.360 clofibrate and niacin in coronary heart disease The Coronary Drug Project Research Group
- Atheroclerosis. v.38 no.273 Fenofibrate therapy of hyperlipoproteinemia:a dose-response study and a comparison with clofibrate Rossner,S.;Oro,L.
- Metabolism v.37 no.217 Hypertriglyceridemia and hyperuricemia:effects of two fibric acid derivative and fenofibrate in a doubleblind,placebo-controlled tral Bastow,M.D.;Durrinaton,P.N.;Ishola,M.
- Am.J.Med. v.83 no.3 Structure and biochemical effects of fenofibrate Kloer,H.U.
- Am.J.Med. v.83 no.3 Structure and biochemical effects of fenofibrate Kloer,H.U.
- Thromb.Hamostasis v.70 no.2 Effect of theree fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia Branchi,A.;Rovellini,A.;Sommariva,D.
- Curr.Ther.Res. v.47 no.952 Fenofibrate and reduction of coronary heart disease Edgar,A.D.
- Drugs. v.54 no.615 Micronised fenofibrate:a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia Adkins,J.C.;Faulds,D.
- Curr.Ther.Res. v.54 no.610 A comparison of the bioavailability of standard or micronized formulation of fenofibrate Guichard JP;Sauron RLP
- Product Information Tricor(TM),micornized fenofibrate capsules
- Diabetes Metab.Rev. v.13 no.93 Triglyceride is the major aterogenic lipid in NIDDM. Taskinen,M.R.
- Diabetologia. v.32 no.300 Hypertrigly-ceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes Fontbonne,A.;Eschwege,E.;Cambien,F.;Richard,J.L.;Ducimetier,P.;Thibult,N.